跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NAT-MONTELUKAST - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NAT-MONTELUKAST
Authorized
STANDARD
NAT-MONTELUKAST
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
5ffdb704ccf7bef2
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
5ffdb704ccf7bef2
Drug Approval Canada Name
NAT-MONTELUKAST
Product Name
NAT-MONTELUKAST
Status
Marketed
Status Date
2022-12-19
Original Market Date
2022-12-19
Din
02522136
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
48:10.24
Atc Original
R03DC03 MONTELUKAST
Atc Name
r 03 dc 03
Aig Number
0133823002
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
MONTELUKAST (MONTELUKAST SODIUM)
10 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
5ffdb704ccf7bef2
Type
Standard
Back to Health Canada Approvals